Innovacell's Strategic Fundraising Efforts
Innovacell, a pioneer in regenerative medicine based in Shinagawa, Tokyo, has recently secured approximately 400 million yen in financing through the public investment trust managed by Reos Capital Works, known as "Hifumi Crossover Pro." This significant funding will contribute to advancing therapies targeting fecal and urinary incontinence through innovative cell treatments, aiming to improve health and quality of life for patients.
The "Hifumi Crossover Pro" fund primarily invests in companies that show potential for growth, including both private and publicly traded ones, ostensibly blurring the lines between these sectors. Currently, Innovacell is actively pursuing Series D funding, with this recent capital raise being part of their strategy through a third-party allocation of shares to the Hifumi Startup Investment Limited Partnership.
Despite having surpassed their initial goal of 3.5 billion yen during this funding round, Innovacell is still negotiating with domestic and international investors for additional resources to fuel their growth further.
Utilizing the Raised Funds
The funds acquired during this fundraising round will strategically support several key initiatives:
1.
Phase III International Joint Clinical Trial: Innovacell plans to expedite the Phase III clinical trials for their regenerative medical product ICEF15, targeting patients suffering from urgency fecal incontinence.
2.
Preparation for U.S. Market Entry: Innovacell is poised to begin preparations for the Phase III clinical trials in the United States, a pivotal step toward global market presence.
3.
Manufacturing and Sales Framework: They aim to establish a robust manufacturing and sales system for ICEF15 in Japan, the U.S., and Europe.
4.
Pipeline Development: Expanding research and development for additional pipeline products beyond ICEF15 is also high on their agenda alongside preparations for a public listing.
Leadership Insights
Colin Lee Novick and Jason David Sieger, Co-CEOs of Innovacell, expressed their gratitude for the partnership with Reos Capital Works through comments emphasizing the importance of their collaborative investment. They highlighted that delivering innovative regenerative and cell therapies to patients with limited treatment options embodies Innovacell's mission. "This funding will empower us to boldly pursue further challenges and deliver groundbreaking pharmaceuticals globally as a bio-venture company."
About Hifumi Crossover Pro
The Hifumi Crossover Pro fund is distinctively positioned to invest in both private and public companies that demonstrate significant growth potential. It not only seeks investment opportunities but also engages in thorough and continuous research to identify promising companies early in their development lifecycle, ensuring proactive investments. This methodology embodies the concept of cross-over investment, blending various fields to foster innovative creations that transcend conventional boundaries.
Innovacell's Background
Founded in 2021, Innovacell emerges as a spinoff from the Medical University of Innsbruck in Austria, focusing on enhancing public health and quality of life through regenerative medicine. The company is committed to developing products that address urgency fecal incontinence and stress urinary incontinence. The most advanced product under development, ICEF15, seeks to harness patients' muscle precursor cells to regenerate muscle tissue through localized administration, targeting a fundamental solution for fecal incontinence. Currently, Innovacell is conducting an international Phase III trial, known as the Fidelia study, across ten European countries and Japan. Previous clinical trials, including late-phase trials for both ICEF15 and ICES13 for stress urinary incontinence, have been completed successfully in Europe.
For more information, visit
Innovacell's website.